|
2025
|
Invention
|
Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses.
The present... |
|
|
Invention
|
Antigen binding molecules that bind bdca-2. The present invention relates antigen binding molecul... |
|
|
Invention
|
Peptide derivatives and related uses as orexin agonists.
The present disclosure relates to pepti... |
|
2024
|
Invention
|
Anti-cd47 binding agents.
The invention relates to antibody molecules and antigen-binding portio... |
|
|
Invention
|
Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof.
Provided herein are pr... |
|
|
Invention
|
Bicyclic-heterocycle derivatives and related uses.
The present disclosure relates to compounds o... |
|
|
Invention
|
Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof. Provided herein are pr... |
|
|
Invention
|
Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof. Provided herein are pr... |
|
2023
|
Invention
|
Compositions and their use for the treatment of a1-antitrypsin deficiency.
The invention relates... |
|
|
Invention
|
Antigen binding molecules that bind light.
The present invention relates antigen binding molecul... |
|
|
Invention
|
2-(3-ethynylbenzyl)-substituted heterocycle derivatives and related uses.
The present disclosure... |
|
|
Invention
|
Anti c-met antibodies. Provided herein are antibody molecules that bind specifically to C-MET and... |
|
2022
|
Invention
|
4-((6-oxopyrimidin-1(6h)-yl)methyl)benzoic acid as an inducer of z a1at secretion for treating aa... |
|
|
Invention
|
Binding agents.
The invention relates to antibody molecules and antigen-binding portions thereof... |
|
|
Invention
|
Compounds and their use for the treatment of alpha1-antitrypsin deficiency. 1-antitrypsin deficie... |
|
|
Invention
|
Compounds and their use for the treatment of alpha1-antitrypsin deficiency.
The invention relate... |
|
|
Invention
|
Antigen binding molecules that bind light. The present invention relates to antigen binding molec... |
|
|
Invention
|
Anti bdca-2 antibodies.
The present invention relates antigen binding molecules, particularly an... |
|
2021
|
Invention
|
Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 rec... |
|
|
Invention
|
Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists.
The present discl... |
|
|
Invention
|
Stat inihibitory compounds and compositions.
Provided herein are compounds and pharmaceutical co... |
|
|
Invention
|
Stat inhibitory compounds and compositions.
Provided herein are compounds and pharmaceutical com... |
|
|
Invention
|
Heterocycle containing stat inhibitors and compositions.
Provided herein are compounds and pharm... |
|
|
Invention
|
Alpha substituted stat inhibitors and compositions thereof.
Provided herein are compounds and ph... |
|
2020
|
Invention
|
Method of using anti-cd47 antibody molecules. The invention relates to antibody molecules and ant... |
|
|
Invention
|
Activatable bispecific antibodies comprising a linker between the two binding domains which is a ... |
|
2019
|
Invention
|
Anti-cd47 antibody molecules. The invention relates to antibody molecules and antigen-binding por... |
|
|
Invention
|
Anti-pd-l1 antibodies.
The present invention relates to antigen binding molecules, particularly ... |
|
|
G/S
|
Pharmaceutical products; pharmaceutical preparations. |
|
|
G/S
|
Pharmaceutical products and preparations for the prevention and treatment of autoimmune, cardiova... |
|
|
Invention
|
Cd47 binding agents. Provided herein are antibody molecules that bind specifically to CD47 and re... |
|
|
Invention
|
Anti c-met antibodies. The present disclosure relates to antibody molecules that bind specificall... |
|
2018
|
Invention
|
Antigen binding molecules that bind light. The present invention relates antigen binding molecule... |
